WONOEP appraisal: Biomarkers of epilepsy-associated comorbidities

Teresa Ravizza, Filiz Y. Onat, Amy R. Brooks-Kayal, Antoine Depaulis, Aristea S. Galanopoulou, Andrey Mazarati, Adam L. Numis, Raman Sankar, Alon Friedman

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Neurologic and psychiatric comorbidities are common in patients with epilepsy. Diagnostic, predictive, and pharmacodynamic biomarkers of such comorbidities do not exist. They may share pathogenetic mechanisms with epileptogenesis/ictogenesis, and as such are an unmet clinical need. The objectives of the subgroup on biomarkers of comorbidities at the XIII Workshop on the Neurobiology of Epilepsy (WONOEP) were to present the state-of-the-art recent research findings in the field that highlighting potential biomarkers for comorbidities in epilepsy. We review recent progress in the field, including molecular, imaging, and genetic biomarkers of comorbidities as discussed during the WONOEP meeting on August 31–September 4, 2015, in Heybeliada Island (Istanbul, Turkey). We further highlight new directions and concepts from studies on comorbidities and potential new biomarkers for the prediction, diagnosis, and treatment of epilepsy-associated comorbidities. The activation of various molecular signaling pathways such as the “Janus Kinase/Signal Transducer and Activator of Transcription,” “mammalian Target of Rapamycin,” and oxidative stress have been shown to correlate with the presence and severity of subsequent cognitive abnormalities. Furthermore, dysfunction in serotonergic transmission, hyperactivity of the hypothalamic-pituitary-adrenocortical axis, the role of the inflammatory cytokines, and the contributions of genetic factors have all recently been regarded as relevant for understanding epilepsy-associated depression and cognitive deficits. Recent evidence supports the utility of imaging studies as potential biomarkers. The role of such biomarker may be far beyond the diagnosis of comorbidities, as accumulating clinical data indicate that comorbidities can predict epilepsy outcomes. Future research is required to reveal whether molecular changes in specific signaling pathways or advanced imaging techniques could be detected in the clinical settings and correlate with epilepsy-associated comorbidities. A reliable biomarker will allow a more accurate diagnosis and improved treatment of epilepsy-associated comorbidities.

Original languageEnglish
Pages (from-to)331-342
Number of pages12
JournalEpilepsia
Volume58
Issue number3
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Neurobiology
Comorbidity
Epilepsy
Biomarkers
Education
Janus Kinases
Molecular Imaging
Sirolimus
Turkey
Transducers
Islands
Nervous System
Psychiatry
Molecular Biology
Oxidative Stress
Cytokines

Keywords

  • Cognition
  • Depression
  • Epilepsy
  • Imaging
  • Neurobehavioral comorbidities
  • Polymorphisms

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Ravizza, T., Onat, F. Y., Brooks-Kayal, A. R., Depaulis, A., Galanopoulou, A. S., Mazarati, A., ... Friedman, A. (2017). WONOEP appraisal: Biomarkers of epilepsy-associated comorbidities. Epilepsia, 58(3), 331-342. https://doi.org/10.1111/epi.13652

WONOEP appraisal : Biomarkers of epilepsy-associated comorbidities. / Ravizza, Teresa; Onat, Filiz Y.; Brooks-Kayal, Amy R.; Depaulis, Antoine; Galanopoulou, Aristea S.; Mazarati, Andrey; Numis, Adam L.; Sankar, Raman; Friedman, Alon.

In: Epilepsia, Vol. 58, No. 3, 01.03.2017, p. 331-342.

Research output: Contribution to journalReview article

Ravizza, T, Onat, FY, Brooks-Kayal, AR, Depaulis, A, Galanopoulou, AS, Mazarati, A, Numis, AL, Sankar, R & Friedman, A 2017, 'WONOEP appraisal: Biomarkers of epilepsy-associated comorbidities', Epilepsia, vol. 58, no. 3, pp. 331-342. https://doi.org/10.1111/epi.13652
Ravizza T, Onat FY, Brooks-Kayal AR, Depaulis A, Galanopoulou AS, Mazarati A et al. WONOEP appraisal: Biomarkers of epilepsy-associated comorbidities. Epilepsia. 2017 Mar 1;58(3):331-342. https://doi.org/10.1111/epi.13652
Ravizza, Teresa ; Onat, Filiz Y. ; Brooks-Kayal, Amy R. ; Depaulis, Antoine ; Galanopoulou, Aristea S. ; Mazarati, Andrey ; Numis, Adam L. ; Sankar, Raman ; Friedman, Alon. / WONOEP appraisal : Biomarkers of epilepsy-associated comorbidities. In: Epilepsia. 2017 ; Vol. 58, No. 3. pp. 331-342.
@article{c7c6f171d2eb4ce09b84f18a211dd3f9,
title = "WONOEP appraisal: Biomarkers of epilepsy-associated comorbidities",
abstract = "Neurologic and psychiatric comorbidities are common in patients with epilepsy. Diagnostic, predictive, and pharmacodynamic biomarkers of such comorbidities do not exist. They may share pathogenetic mechanisms with epileptogenesis/ictogenesis, and as such are an unmet clinical need. The objectives of the subgroup on biomarkers of comorbidities at the XIII Workshop on the Neurobiology of Epilepsy (WONOEP) were to present the state-of-the-art recent research findings in the field that highlighting potential biomarkers for comorbidities in epilepsy. We review recent progress in the field, including molecular, imaging, and genetic biomarkers of comorbidities as discussed during the WONOEP meeting on August 31–September 4, 2015, in Heybeliada Island (Istanbul, Turkey). We further highlight new directions and concepts from studies on comorbidities and potential new biomarkers for the prediction, diagnosis, and treatment of epilepsy-associated comorbidities. The activation of various molecular signaling pathways such as the “Janus Kinase/Signal Transducer and Activator of Transcription,” “mammalian Target of Rapamycin,” and oxidative stress have been shown to correlate with the presence and severity of subsequent cognitive abnormalities. Furthermore, dysfunction in serotonergic transmission, hyperactivity of the hypothalamic-pituitary-adrenocortical axis, the role of the inflammatory cytokines, and the contributions of genetic factors have all recently been regarded as relevant for understanding epilepsy-associated depression and cognitive deficits. Recent evidence supports the utility of imaging studies as potential biomarkers. The role of such biomarker may be far beyond the diagnosis of comorbidities, as accumulating clinical data indicate that comorbidities can predict epilepsy outcomes. Future research is required to reveal whether molecular changes in specific signaling pathways or advanced imaging techniques could be detected in the clinical settings and correlate with epilepsy-associated comorbidities. A reliable biomarker will allow a more accurate diagnosis and improved treatment of epilepsy-associated comorbidities.",
keywords = "Cognition, Depression, Epilepsy, Imaging, Neurobehavioral comorbidities, Polymorphisms",
author = "Teresa Ravizza and Onat, {Filiz Y.} and Brooks-Kayal, {Amy R.} and Antoine Depaulis and Galanopoulou, {Aristea S.} and Andrey Mazarati and Numis, {Adam L.} and Raman Sankar and Alon Friedman",
year = "2017",
month = "3",
day = "1",
doi = "10.1111/epi.13652",
language = "English",
volume = "58",
pages = "331--342",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Blackwell Publishing Inc.",
number = "3",

}

TY - JOUR

T1 - WONOEP appraisal

T2 - Biomarkers of epilepsy-associated comorbidities

AU - Ravizza, Teresa

AU - Onat, Filiz Y.

AU - Brooks-Kayal, Amy R.

AU - Depaulis, Antoine

AU - Galanopoulou, Aristea S.

AU - Mazarati, Andrey

AU - Numis, Adam L.

AU - Sankar, Raman

AU - Friedman, Alon

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Neurologic and psychiatric comorbidities are common in patients with epilepsy. Diagnostic, predictive, and pharmacodynamic biomarkers of such comorbidities do not exist. They may share pathogenetic mechanisms with epileptogenesis/ictogenesis, and as such are an unmet clinical need. The objectives of the subgroup on biomarkers of comorbidities at the XIII Workshop on the Neurobiology of Epilepsy (WONOEP) were to present the state-of-the-art recent research findings in the field that highlighting potential biomarkers for comorbidities in epilepsy. We review recent progress in the field, including molecular, imaging, and genetic biomarkers of comorbidities as discussed during the WONOEP meeting on August 31–September 4, 2015, in Heybeliada Island (Istanbul, Turkey). We further highlight new directions and concepts from studies on comorbidities and potential new biomarkers for the prediction, diagnosis, and treatment of epilepsy-associated comorbidities. The activation of various molecular signaling pathways such as the “Janus Kinase/Signal Transducer and Activator of Transcription,” “mammalian Target of Rapamycin,” and oxidative stress have been shown to correlate with the presence and severity of subsequent cognitive abnormalities. Furthermore, dysfunction in serotonergic transmission, hyperactivity of the hypothalamic-pituitary-adrenocortical axis, the role of the inflammatory cytokines, and the contributions of genetic factors have all recently been regarded as relevant for understanding epilepsy-associated depression and cognitive deficits. Recent evidence supports the utility of imaging studies as potential biomarkers. The role of such biomarker may be far beyond the diagnosis of comorbidities, as accumulating clinical data indicate that comorbidities can predict epilepsy outcomes. Future research is required to reveal whether molecular changes in specific signaling pathways or advanced imaging techniques could be detected in the clinical settings and correlate with epilepsy-associated comorbidities. A reliable biomarker will allow a more accurate diagnosis and improved treatment of epilepsy-associated comorbidities.

AB - Neurologic and psychiatric comorbidities are common in patients with epilepsy. Diagnostic, predictive, and pharmacodynamic biomarkers of such comorbidities do not exist. They may share pathogenetic mechanisms with epileptogenesis/ictogenesis, and as such are an unmet clinical need. The objectives of the subgroup on biomarkers of comorbidities at the XIII Workshop on the Neurobiology of Epilepsy (WONOEP) were to present the state-of-the-art recent research findings in the field that highlighting potential biomarkers for comorbidities in epilepsy. We review recent progress in the field, including molecular, imaging, and genetic biomarkers of comorbidities as discussed during the WONOEP meeting on August 31–September 4, 2015, in Heybeliada Island (Istanbul, Turkey). We further highlight new directions and concepts from studies on comorbidities and potential new biomarkers for the prediction, diagnosis, and treatment of epilepsy-associated comorbidities. The activation of various molecular signaling pathways such as the “Janus Kinase/Signal Transducer and Activator of Transcription,” “mammalian Target of Rapamycin,” and oxidative stress have been shown to correlate with the presence and severity of subsequent cognitive abnormalities. Furthermore, dysfunction in serotonergic transmission, hyperactivity of the hypothalamic-pituitary-adrenocortical axis, the role of the inflammatory cytokines, and the contributions of genetic factors have all recently been regarded as relevant for understanding epilepsy-associated depression and cognitive deficits. Recent evidence supports the utility of imaging studies as potential biomarkers. The role of such biomarker may be far beyond the diagnosis of comorbidities, as accumulating clinical data indicate that comorbidities can predict epilepsy outcomes. Future research is required to reveal whether molecular changes in specific signaling pathways or advanced imaging techniques could be detected in the clinical settings and correlate with epilepsy-associated comorbidities. A reliable biomarker will allow a more accurate diagnosis and improved treatment of epilepsy-associated comorbidities.

KW - Cognition

KW - Depression

KW - Epilepsy

KW - Imaging

KW - Neurobehavioral comorbidities

KW - Polymorphisms

UR - http://www.scopus.com/inward/record.url?scp=85007493425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007493425&partnerID=8YFLogxK

U2 - 10.1111/epi.13652

DO - 10.1111/epi.13652

M3 - Review article

C2 - 28035782

AN - SCOPUS:85007493425

VL - 58

SP - 331

EP - 342

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 3

ER -